A Personalized T-Cell Therapy Cleared a Teenager's Metastatic Kidney Cancer. A Real Trial Comes Next.

The patient was seven when the kidney tumor first showed up. Over the following ten years it kept coming back — relapse after relapse, eventually spreading into large metastatic lesions in the abdomen, the kind of treatment-resistant progression that tends to run out of options. Doctors at Hopp Children's Cancer Center Heidelberg (KiTZ), working with several other leading cancer centers, tried something different: a personalized T-cell therapy, built specifically for this one patient under compassionate-use rules rather than as part of a formal trial. The disease reversed completely. No detectable tumor remained, despite the metastases. The case has now been published in the New England Journal of Medicine.

The therapy targets a protein called PRAME, which shows up far more often than you'd expect in high-risk pediatric tumors. That's not a guess — it comes from tumor data on more than 2,500 patients gathered through the INFORM study, which is what made PRAME look like a genuinely promising target in the first place rather than a long shot. The biotech company Immatics supplied the viral vector used to reprogram the patient's own immune cells to recognize and attack PRAME-positive tumor cells. One patient, one case, one publication — that's the honest scope of what's been shown so far. It's a striking result, but it's not yet evidence of how well this works across a real patient population, and the researchers involved aren't claiming otherwise.

That's exactly why a proper trial is now being built around it. KiTZ is preparing a Phase I/II clinical trial called PRAMEtime, aimed at children and adolescents aged 8 to 17 with PRAME-positive solid tumors — up to 18 patients, enrollment starting in 2027. It's worth sitting with that gap for a second: from this single successful case to the first structured trial testing whether it holds up more broadly, well over a year will have passed. That's not a criticism of the pace — matching cell manufacturing capacity, trial design, and regulatory review to a therapy this personalized takes real time — but it's a useful reminder of how far "one patient's cancer disappeared" is from "this treatment works."

The manufacturing side is being built out at the same time. Future batches of these engineered T cells are slated to come from the newly established Center for Innovative Therapies in Heidelberg, a joint venture between University Hospital Heidelberg and the German Cancer Research Center that only opened in June 2026, with Immatics continuing to provide the vector specifically for PRAME-targeted work. None of that infrastructure existed when this particular patient was treated — which is really the story here: not just that a hard case was rescued, but that everything needed to try it again, on purpose, at a small but real scale, is now actually being put in place.